Century Therapeutics exec sells 2,587 shares

Century Therapeutics, Inc. (IPSC) executive Gregory Russotti, Chief Technology and Manufacturing Officer, reported an automatic sale of 2,587 shares of common stock on September 14, 2026 at $1.93 per share.

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) executive Gregory Russotti, Chief Technology and Manufacturing Officer, reported an automatic sale of 2,587 shares of common stock on September 14, 2026 at $1.93 per share. The footnote states these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units and the sale was not at his discretion.

After the transaction, Russotti holds 509,198 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Seller: 2,587 shares

Net Sell 2 txns

Insider Russotti Gregory

Role See Remarks

Sold 2,587 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,587	$1.93	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 509,198 shares (Direct); Common Stock — 92,773 shares (Indirect, By Gregory Russotti 2021 Family Trust)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Key Figures

Shares sold: 2,587 shares Sale price per share: $1.93 per share Direct holdings after transaction: 509,198 shares +1 more

4 metrics

Shares sold 2,587 shares Common stock sold on September 14, 2026

Sale price per share $1.93 per share Price for the 2,587 common shares sold

Direct holdings after transaction 509,198 shares Direct Century Therapeutics common stock held after sale

Indirect holdings after transaction 92,773 shares Indirect holdings by Gregory Russotti 2021 Family Trust

Key Terms

restricted stock units, tax withholding obligations, indirect

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares required to be sold ... to cover tax withholding obligations"

indirect financial

"Indirect ownership by Gregory Russotti 2021 Family Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IPSC executive Gregory Russotti report?

Gregory Russotti reported selling 2,587 shares of Century Therapeutics common stock on September 14, 2026 at $1.93 per share. The filing states the sale was made automatically to cover tax withholding obligations from vesting restricted stock units.

Why were shares of IPSC sold by Gregory Russotti in this Form 4?

The filing states the sale represented shares required to be sold to cover tax withholding obligations related to the vesting of restricted stock units. It notes the sales were automatic and not at the discretion of Gregory Russotti.

How many IPSC shares did Gregory Russotti retain directly after the reported sale?

After the transaction, Gregory Russotti held 509,198 shares of Century Therapeutics common stock directly. This figure is reported as his total direct holding following the sale on September 14, 2026.

Does Gregory Russotti have indirect ownership of IPSC shares?

Yes. The Form 4 reports 92,773 shares of Century Therapeutics common stock held indirectly by the Gregory Russotti 2021 Family Trust. These are reported separately from his direct ownership position.

Was the IPSC insider sale made under a Rule 10b5-1 trading plan?

The document-level indicator shows no Rule 10b5-1 plan is reported. The footnote instead explains that the sales were automatic to satisfy tax withholding obligations from RSU vesting, and not at the reporting person’s discretion.

What role does Gregory Russotti hold at Century Therapeutics (IPSC)?

The Form 4 identifies Gregory Russotti as an officer of Century Therapeutics with the title Chief Technology and Manufacturing Officer, as reflected in the remarks section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 06:26 PM Accepted by SEC EDGAR 09/15/2026 - 06:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russotti Gregory

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 12TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S(1)		2,587	D	$1.93	509,198	D
Common Stock								92,773	I	By Gregory Russotti 2021 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Remarks:

Title: Chief Technology and Manufacturing Officer

	/s/ Douglas Carr, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)